TriPRIL CAR T / Massachusetts General Hospital - LARVOL DELTA

First-in-Human Phase 1 Trial of Trimeric APRIL (TriPRIL) CAR-T Cells in Relapsed or Refractory Multiple Myeloma (IMS 2025) - "Lymphodepletion consisted of cyclophosphamide 300 mg/m2 and fludarabine 30 mg/m2 on Days -5 to -3. TriPRIL CAR-T cells demonstrated overall safety in patients with R/R MM with no DLT occurrences. Moreover, TriPRIL CAR-T cells showed high response rates with durable responses notably seen even in patients who had progressed after prior BCMA-directed CAR-T cell therapy. This study highlights the potential of this novel dual-antigen CAR-T cell therapy in both CAR-naïve and CAR-exposed R/R MM patients."

CAR T-Cell Therapy • First-in-human • P1 data • CNS Disorders • Hematological Malignancies • Infectious Disease • Movement Disorders • Multiple Myeloma • Parkinson's Disease

First-in-human phase 1 trial of trimeric APRIL (TriPRIL) CAR T cells in relapsed or refractory multiple myeloma: Clinical outcomes and biological correlates of disease response and resistance (ASH 2025) - P1 | "Our findings support and informthe continued clinical development of TriPRIL CAR T cells. Updated data through November 2025 will bepresented."

CAR T-Cell Therapy • Clinical • Clinical data • First-in-human • IO biomarker • P1 data • CNS Disorders • Hematological Malignancies • Movement Disorders • Multiple Myeloma • Parkinson's Disease

TriPRIL CAR T Cells in Multiple Myeloma (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Marcela V. Maus, M.D.,Ph.D. | Trial completion date: Jan 2025 ➔ Jan 2028 | Trial primary completion date: Jan 2024 ➔ Jan 2026

CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology